Klin Farmakol Farm. 2022;36(4):146-149 | DOI: 10.36290/far.2022.024

Recent advances in research of Silymarin and its components

Jan Soukop, Rostislav Večeřa
Ústav farmakologie, Lékařská fakulta Univerzity Palackého v Olomouci

Silymarin, a standardized extract from the Silybum marianum fruit, is a proven natural food supplement that is used to support the treatment of a number of pathological conditions of the organism. Metformin administered with silymarin may reduce the development of hepatic steatosis, especially in the prediabetic state. Fenofibrate in combination with silymarin can reduce lipo­peroxidation and CYP2E1 expression (and thus ROS production) which contributes to reducing the risk of developing complications of steatosis in the liver. Mechanism of its hypolipidemic effect does not work via activation of PPARα receptors (as it does in the case of fibrates), but probably in the reduction of cholesterol absorption from the intestine (which is also the effect of its polymer fraction) or in the increased expression of cytochromes P450 involved in the metabolism and excretion of cholesterol. Upregulation of transport proteins ABCG5 and ABCG8 by silymarin and n-3 PUFA reduces the level of triglycerides and total cholesterol, which can act preventively in the development of metabolic disorders caused by hypertriglyceridemia. The stated conclusions of in vivo studies show a positive effect of silymarin (whether its component or whole) on the organism in the prevention or supportive treatment of a number of diseases, including metabolic syndrome.

Keywords: natural polyphenols, silymarin, silybin, isosilybin, silychristin, silydianin, taxifolin.

Accepted: February 8, 2023; Published: February 8, 2023  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Soukop J, Večeřa R. Recent advances in research of Silymarin and its components. Klin Farmakol Farm. 2022;36(4):146-149. doi: 10.36290/far.2022.024.
Download citation

References

  1. Pourová J, et al. The Effect of Silymarin Flavonolignans and Their Sulfated Conjugates on Platelet Aggregation and Blood Vessels Ex Vivo. Nutrients 2019;11(10). Go to original source... Go to PubMed...
  2. Petrásková L, Káňová K, Biedermann D, Kren V, Valentová K. Simple and Rapid HPLC Separation and Quantification of Flavonoid, Flavonolignans, and 2,3-Dehydroflavonolignans in Silymarin. Foods 2020;9(2):116. Go to original source... Go to PubMed...
  3. Chambers CS, et al. The silymarin composition… and why does it matter???. Int. Food Res. 2017;100:339-353. Go to original source... Go to PubMed...
  4. Koltai T, Fliegel L. Role of Silymarin in Cancer Treatment: Facts, Hypotheses, and Questions. J. Evid. Based Integr. Med. 2022;27. doi:10.1177/2515690X211068826/FORMAT/EPUB. Go to original source...
  5. Škottová N, et al. Effects of polyphenolic fraction of silymarin on lipoprotein profile in rats fed cholesterol-rich diets. Pharmacol. Res. 2003;47(1):17-26. Go to original source... Go to PubMed...
  6. Sobolová L, Škottová N, Večeřa R, Urbánek K. Effect of silymarin and its polyphenolic fraction on cholesterol absorption in rats. Pharmacol. Res. 2006;53(2):104-112. Go to original source... Go to PubMed...
  7. Vecera R, Zacharova A, Orolin J, Skottova N, Anzenbacher P. The effect of silymarin on expression of selected ABC transporters in the rat. Vet. Med. (Praha) 2011;56(2):59-62. Go to original source...
  8. Orolin J, et al. Hypolipidemic effects of silymarin are not mediated by the peroxisome proliferator-activated receptor alpha. Xenobiotica 2007;37(7):725-735. Go to original source... Go to PubMed...
  9. Zicha J, et al. Hereditary hypertriglyceridemic rat: a suitable model of cardiovascular disease and metabolic syndrome? Physiol. Res. 2006;55 Suppl 1(SUPPL. 1). doi:10.33549/PHYSIOLRES.930000.55.S1.49. Go to original source... Go to PubMed...
  10. Poruba M, et al. Positive effects of different drug forms of silybin in the treatment of metabolic syndrome. Physiol. Res. 2015;64(Suppl 4):507-512. Go to original source... Go to PubMed...
  11. Poruba M, et al. The effect of combined diet containing n-3 polyunsaturated fatty acids and silymarin on metabolic syndrome in rats. Physiol. Res. 2019;68(Suppl 1):39-50. Go to original source... Go to PubMed...
  12. Hüttl M, et al. The Beneficial Additive Effect of Silymarin in Metformin Therapy of Liver Steatosis in a Pre-Diabetic Model. Pharmaceutics 2021;14(1). Go to original source... Go to PubMed...
  13. Večeřa R, et al. Beneficial Effect of Fenofibrate and Silymarin on Hepatic Steatosis and Gene Expression of Lipogenic and Cytochrome P450 Enzymes in Non-Obese Hereditary Hypertriglyceridemic Rats. Cur. Issues Mol. Biol. 2022;44(5):1889-1900. Go to original source... Go to PubMed...
  14. Bijak M. Silybin, a Major Bioactive Component of Milk Thistle (Silybum marianum L. Gaernt.) - Chemistry, Bioavailability, and Metabolism. Molecules. 2017;22(11). Go to original source... Go to PubMed...
  15. Plíšková M, et al. Effects of silymarin flavonolignans and synthetic silybin derivatives on estrogen and aryl hydrocarbon receptor activation. Toxicology 2005;215(1-2):80-89. Go to original source... Go to PubMed...
  16. Večeřa R, et al. Silybin affects the liver microsomal CYP2C6 in HHTg rats. Biomed. Pap. Med.Fac. 2013;157(1):60-64.
  17. Wang X lu, et al. Silybin B exerts protective effect on cisplatin-induced neurotoxicity by alleviating DNA damage and apoptosis. J. Ethnopharmacol. 2022; 288:114938. Go to original source... Go to PubMed...
  18. Wang X, et al. Berberine-photodynamic therapy sensitizes melanoma cells to cisplatin-induced apoptosis through ROS-mediated P38 MAPK pathways. Toxicol. Appl. Pharmacol. 2021; 418:115484. Go to original source... Go to PubMed...
  19. Yang Q, et al. PINK1 Protects Auditory Hair Cells and Spiral Ganglion Neurons from Cisplatin-induced Ototoxicity via Inducing Autophagy and Inhibiting JNK Signaling Pathway. Free Radic. Biol. Med. 2018;120:342-355. Go to original source... Go to PubMed...
  20. Šeršeň F, Vencel T, Annus J. Silymarin and its components scavenge phenylglyoxylic ketyl radicals. Fitoterapia 2006;77(7-8):525-529. Go to original source... Go to PubMed...
  21. Liu X, et al. Isosilybin regulates lipogenesis and fatty acid oxidation via the AMPK/SREBP-1c/PPARα pathway. Chem. Biol. Interact. 2022;368:110250. Go to original source... Go to PubMed...
  22. Biedermann D, et al. Silychristin: Skeletal Alterations and Biological Activities. J. Nat. Prod. 2016;79(12):3086-3092. Go to original source... Go to PubMed...
  23. Křenek K, Marhol P, Peikerová, Křen V, Biedermann D. Preparatory separation of the silymarin flavonolignans by Sephadex LH-20 gel. Int. Food Res. J. 2014;65(PA):115-120. Go to original source...
  24. Viktorová J, et al. Antioxidant, Anti-Inflammatory, and Multidrug Resistance Modulation Activity of Silychristin Derivatives. Antioxidants 2019;8(8):303. Go to original source... Go to PubMed...
  25. Wang J, et al. Silychristin A activates Nrf2-HO-1/SOD2 pathway to reduce apoptosis and improve GLP-1 production through upregulation of estrogen receptor α in GLUTag cells. Eur J. Pharmacol. 2020;881:173236. Go to original source... Go to PubMed...
  26. Biedermann D, et al. Oxidation of flavonolignan silydianin to unexpected lactone-acid derivative. Phytochem. Lett. 2019;30:14-20. Go to original source...
  27. Zielińska-Przyjemska M, Wiktorowicz K. An in vitro study of the protective effect of the flavonoid silydianin against reactive oxygen species. Phytother. Res. 2006;20(2): 115-119. Go to original source... Go to PubMed...
  28. Lv Y, et al. Spatial organization of silybin biosynthesis in milk thistle [Silybum marianum (L.) Gaertn]. Plant Journal 2017;92(6):995-1004. Go to original source... Go to PubMed...
  29. Vostálová J, et al. Skin protective activity of silymarin and its flavonolignans. Molecules 2019;24(6). Go to original source... Go to PubMed...
  30. Zholobenko A, Modriansky M. Silymarin and its constituents in cardiac preconditioning. Fitoterapia 2014;97:122-132. Go to original source... Go to PubMed...
  31. Sato M, et al. Structure-activity relationship for (+)-taxifolin isolated from silymarin as an inhibitor of amyloid β aggregation. Biosci. Biotechnol. Biochem. 2013;77(5):1100-1103. Go to original source... Go to PubMed...




Clinical Pharmacology and Pharmacy

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.